福泰制药（Vertex Pharmaceuticals）宣布，其在研药物Povetacicept针对成人IgA肾病的三期临床试验（代号Rainier）第36周中期分析结果积极。数据显示，该试验不仅达到主要终点，所有预设的次要终点也均呈现统计学显著改善。这一进展为IgA肾病治疗领域带来新的希望。
福泰制药（Vertex Pharmaceuticals）宣布，其在研药物Povetacicept针对成人IgA肾病的三期临床试验（代号Rainier）第36周中期分析结果积极。数据显示，该试验不仅达到主要终点，所有预设的次要终点也均呈现统计学显著改善。这一进展为IgA肾病治疗领域带来新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.